466 related articles for article (PubMed ID: 31880103)
41. Recurrent bladder carcinoma: clinical and prognostic role of 18 F-FDG PET/CT.
Alongi P; Caobelli F; Gentile R; Stefano A; Russo G; Albano D; Baldari S; Gilardi MC; Midiri M
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):224-233. PubMed ID: 27565154
[TBL] [Abstract][Full Text] [Related]
42. Prognostic value of pretreatment volume-based quantitative
Kitajima K; Doi H; Kuribayashi K; Hashimoto M; Tsuchitani T; Tanooka M; Fukushima K; Nakano T; Hasegawa S; Hirota S
Eur J Radiol; 2017 Jan; 86():176-183. PubMed ID: 28027744
[TBL] [Abstract][Full Text] [Related]
43. Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma.
Kim JW; Oh JS; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY
Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1353-61. PubMed ID: 26067088
[TBL] [Abstract][Full Text] [Related]
44. The role of pre-treatment and mid-treatment 18F-FDG PET/CT imaging in evaluating prognosis of peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS).
Zhang Y; Wang G; Zhao X; Hu Y; Tan Su Yin E; Chen D; Wang H; Zhao K
BMC Med Imaging; 2021 Oct; 21(1):145. PubMed ID: 34627196
[TBL] [Abstract][Full Text] [Related]
45. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
[TBL] [Abstract][Full Text] [Related]
46. Pretreatment quantitative
Gencturk M; Ozturk K; Koksel Y; Li F; Cayci Z
Clin Imaging; 2019; 53():17-24. PubMed ID: 30308429
[TBL] [Abstract][Full Text] [Related]
47. Volume-based quantitative FDG PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery.
Vargas HA; Burger IA; Goldman DA; Miccò M; Sosa RE; Weber W; Chi DS; Hricak H; Sala E
Eur Radiol; 2015 Nov; 25(11):3348-53. PubMed ID: 25916387
[TBL] [Abstract][Full Text] [Related]
48. Prognostic value of baseline total metabolic tumour volume of
Gong H; Li T; Li J; Tang L; Ding C
EJNMMI Res; 2021 Jul; 11(1):64. PubMed ID: 34264417
[TBL] [Abstract][Full Text] [Related]
49. Prognostic Value of
Albano D; Camoni L; Giubbini R; Bertagna F
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e897-e904. PubMed ID: 32703751
[TBL] [Abstract][Full Text] [Related]
50. Use of
Rudžianskas V; Korobeinikova E; Rudžianskienė M; Jaselskė E; Adlienė D; Šedienė S; Kulakienė I; Padervinskis E; Jurkienė N; Juozaitytė E
Medicina (Kaunas); 2018 Dec; 54(6):. PubMed ID: 30544718
[No Abstract] [Full Text] [Related]
51. [Prognostic value of (18)F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) in extensive-stage small cell lung cancer].
Ding CY; Guo Z; Li YY; Li TR
Zhonghua Zhong Liu Za Zhi; 2017 Nov; 39(11):828-834. PubMed ID: 29151289
[No Abstract] [Full Text] [Related]
52. [Value of
Zhang YY; Chen WY; Cui YP; Gao XR; Hu JX; Li ZZ; Hu K
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1342-1249. PubMed ID: 30295248
[TBL] [Abstract][Full Text] [Related]
53. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R
Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011
[TBL] [Abstract][Full Text] [Related]
54. Can metabolic tumor parameters on primary staging
Okuyucu K; Alagoz E; Ince S; Ozaydin S; Arslan N
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(1):9-14. PubMed ID: 28733137
[TBL] [Abstract][Full Text] [Related]
55. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
[TBL] [Abstract][Full Text] [Related]
56. Comparison of the prognostic values of
Lim CH; Hyun SH; Moon SH; Cho YS; Choi JY; Lee KH
Sci Rep; 2020 Jul; 10(1):12748. PubMed ID: 32728134
[TBL] [Abstract][Full Text] [Related]
57. Prognostic value of metabolic parameters determined by preoperative ¹⁸F-FDG PET/CT in patients with uterine carcinosarcoma.
Lee HJ; Lee JJ; Park JY; Kim JH; Kim YM; Kim YT; Nam JH
J Gynecol Oncol; 2017 Jul; 28(4):e43. PubMed ID: 28541634
[TBL] [Abstract][Full Text] [Related]
58. Prognostic significance of metabolic parameters measured by
Chang H; Lee SJ; Lim J; Lee JS; Kim YJ; Lee WW
J Cancer Res Clin Oncol; 2019 May; 145(5):1361-1367. PubMed ID: 30900157
[TBL] [Abstract][Full Text] [Related]
59. Prognostic Role of 2-[
Albano D; Dondi F; Mazzoletti A; Bellini P; Rodella C; Bertagna F
Diagnostics (Basel); 2021 Nov; 11(12):. PubMed ID: 34943426
[TBL] [Abstract][Full Text] [Related]
60. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative 18F-FDG PET/CT in Patients With Very Early and Early Hepatocellular Carcinoma.
Hwang SH; Lee JW; Cho HJ; Kim KS; Choi GH; Yun M
Clin Nucl Med; 2017 Jan; 42(1):34-39. PubMed ID: 27775949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
